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Many countries are stockpiling face masks for use as a 
nonpharmaceutical intervention to control virus transmission 
during an inﬂ  uenza pandemic. We conducted a prospective 
cluster-randomized trial comparing surgical masks, non–ﬁ  t-
tested P2 masks, and no masks in prevention of inﬂ  uenza-
like illness (ILI) in households. Mask use adherence was 
self-reported. During the 2006 and 2007 winter seasons, 
286 exposed adults from 143 households who had been 
exposed to a child with clinical respiratory illness were re-
cruited. We found that adherence to mask use signiﬁ  cantly 
reduced the risk for ILI-associated infection, but <50% of 
participants wore masks most of the time. We concluded 
that household use of face masks is associated with low 
adherence and is ineffective for controlling seasonal respi-
ratory disease. However, during a severe pandemic when 
use of face masks might be greater, pandemic transmission 
in households could be reduced.    
H
ighly pathogenic avian inﬂ  uenza virus A (H5N1) con-
tinues to spread globally, posing a serious human pan-
demic threat. In the event of an inﬂ  uenza pandemic or other 
emerging respiratory disease such as severe acute respira-
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tory syndrome (SARS), it is likely that antiviral drugs and 
vaccines will be in short supply or that delivery could be 
delayed. Therefore, nonpharmaceutical interventions such 
as mask use, handwashing, and other hygiene measures or 
school closure might be effective early control strategies. 
In contrast to pharmaceutical interventions, little is known 
about the effectiveness of nonpharmaceutical interventions 
in the community. A recent analysis gives estimates of the 
effect of school closure (1), and several prospective, ran-
domized controlled trials of handwashing have been pub-
lished (2–11). However, clinical trial data on the ability 
of face masks to reduce respiratory virus transmission in 
the community are limited to 1 published prospective trial, 
which showed lack of efﬁ  cacy (12). In addition, adverse ef-
fects of wearing masks (particularly respirators) may affect 
compliance and effectiveness (13–15). Despite the lack of 
quantitative evidence, many countries have included rec-
ommendations in their pandemic plans on the use of face 
masks (16–18). We present the results of a cluster-random-
ized household study of the effectiveness of using face 
masks to prevent or reduce transmission of inﬂ  uenza-like 
illness (ILI). 
Methods
A prospective, cluster-randomized trial of mask use in 
households was conducted during the 2 winter seasons of 
2006 and 2007 (August to the end of October 2006 and 
June to the end of October 2007) in Sydney, Australia. 
Enrollment in the study was restricted to households with 
>2 healthy adults >16 years of age; the adults had known 
exposure within the household to a child with fever and 
respiratory symptoms. Suitable households were identi-
ﬁ  ed at a pediatric health service comprising the emergency 
department of a pediatric hospital and a pediatric primary 
care practice in Sydney, New South Wales, Australia. The 
study protocol was approved by the local institutional re-
view board.
Randomization and Intervention 
Participating households were randomized to 1 of 3 
arms by a secure computerized randomization process: 
1) surgical masks (3M surgical mask, catalogue no. 1820; 
St. Paul, MN, USA) for 2 adults, to be worn at all times 
when in the same room as the index child, regardless of 
the distance from the child; 2) P2 masks (3M ﬂ  at-fold P2 
mask, catalogue no. 9320; Bracknell, Berkshire, UK), for 
2 adults, to be worn at all times when in the same room as 
the index child, regardless of the distance from the child; 
and 3) a control group (no masks used). The P2 masks used 
have an almost identical speciﬁ  cation as N95 masks used 
in the United States (19). According to New South Wales 
Health guidelines, pamphlets about infection control were 
provided to participants in all arms. Study participants and 
trial staff were not blinded, as it is not technically possible 
to blind the mask type to which participants were random-
ized. However, laboratory staff were blinded to the arm of 
randomization. Figure 1 shows the ﬂ  ow diagram for the 
trial as suggested by CONSORT guidelines (20). 
Recruitment and Follow-up 
Children 0–15 years of age seeking treatment at pe-
diatric health services with fever (temperature >37.8oC) 
and either cough or sore throat were identiﬁ  ed by an elec-
tronic triage system. Parents or primary caregivers were 
approached in the waiting room, and that household was 
invited to join the study if all of the following criteria were 
satisﬁ  ed: 1) the household contained >2 adults >16 years 
of age and 1 child 0–15 years of age; 2) the index child 
had fever (temperature >37.8oC) and either a cough or sore 
throat; 3) the child was the ﬁ  rst and only person to become 
ill in the family in the previous 2 weeks; 4) adult caregivers 
consented to participate in the study; and 5) the index child 
was not admitted to the hospital. 
If eligibility criteria were satisﬁ  ed, adults from the 
household were enrolled in the study. Enrolled adults and 
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Did not meet inclusion criteria (adults unwell, <1 
adult in household, limited English), n = 256 
Randomized, n = 145 
Control intervention 
  Received allocated intervention 
  52 families (104 adults) 
  Lost to follow up: 2 
Surgical mask intervention 
  Received allocated intervention 
  47 families (94 adults) 
  Lost to follow up: 0 
P2 mask intervention 
  Received allocated intervention 
  46 families (92 adults) 
  Lost to follow up: 0 
Analyzed 
  50 families including 100 adults 
  Excluded from analysis: 2 
Analyzed 
  47 families including 94 adults 
  Excluded from analysis: 0 
Analyzed 
  46 families including 92 adults 
  Excluded from analysis: 0 
Assessed for eligibility, N = 401 
Figure 1. Flow diagram 
of recruitment for the pro-
spective cluster–random-
ized trial, Sydney,  New 
South Wales, Australia, 
2006 and 2007 winter 
inﬂ  uenza seasons.Face Masks and Respiratory Virus Transmission
any siblings of the index child were then evaluated for 
respiratory symptoms and signs (fever, history of fever 
or feeling feverish in the past week, myalgia, arthralgia, 
sore throat, cough, sneezing, runny nose, nasal congestion, 
headache). If any of these symptoms were present, the fam-
ily and household were excluded. Sociodemographic and 
medical information including inﬂ  uenza vaccination his-
tory (both the index child and participating adults) was ob-
tained using a researcher-administered questionnaire. Med-
ication use was also recorded. The index case-patient had 
combined nasal (each nostril) and throat swabs collected 
for multiplex reverse transcription–PCR (RT-PCR) testing. 
The household was randomized to 1 of the 3 arms, allocat-
ed the appropriate mask type, and educated about infection 
prevention. Formal ﬁ  t testing of the P2 masks was not per-
formed, but information pertaining to the correct method 
for ﬁ  tting and disposing of the masks was provided. Over 
the next week, participants were contacted by telephone 
daily to determine if symptoms had developed and to re-
cord adherence to mask use throughout the day. 
Each household was supplied with a thermometer to 
measure the temperature of symptomatic adult participants 
twice daily. If study staff determined that a participant had 
developed respiratory disease symptoms at follow-up, a 
home visit was conducted on the same day and the par-
ticipant was swabbed and tested for respiratory viruses (see 
methods described below). Symptomatic participants were 
then followed up daily for 2 weeks. 
Because all respiratory pathogens share similar trans-
mission mechanisms—aerosol, droplet, and fomite spread 
(although the relative role of these factors may vary among 
different viruses and in different clinical situations)—we 
deliberately considered a broad deﬁ  nition of clinical cases 
consistent with a wide range of common respiratory vi-
ruses. Respiratory viruses detected in the study included 
inﬂ  uenza A and B, respiratory syncytial virus (RSV), ad-
enovirus, parainﬂ  uenza viruses (PIV) types 1–3, coronavi-
ruses 229E and OC43, human metapneumovirus (hMPV), 
enteroviruses, and rhinoviruses. 
Adherence to face mask use was speciﬁ  cally moni-
tored during each household follow-up. Measuring adher-
ence and reasons for nonadherence is critical for evaluat-
ing the efﬁ  cacy of mask use for reducing treatment and for 
providing practical advice on future use of face masks. Exit 
interviews with participants in the surgical mask and the 
P2 mask arms were conducted to gain further insights into 
adherence. 
Sample Collection and Laboratory Testing 
Rayon-tipped, plastic-shafted swabs were inserted sep-
arately into each participant’s nostrils and pharynx, placed 
into viral transport media, and transported immediately to 
the laboratory or stored at 4oC if transport was delayed. 
Nose and throat swabs of index children and adult partici-
pants with symptoms of respiratory illness were tested by 
using nucleic acid and a series of multiplex RT-PCR tests 
(21) to detect inﬂ  uenza A and B and RSV, PIV types 1–3, 
picornaviruses (enteroviruses or rhinoviruses), adenovirus-
es, coronaviruses 229E and OC43, and hMPV. 
Case Deﬁ  nition 
To include the broadest possible spectrum of clinical 
syndromes occurring among enrolled adults (22), during 
follow-up we deﬁ  ned ILI by the presence of fever (tem-
perature >37.8°C), feeling feverish or a history of fever, 
>2 symptoms (sore throat, cough, sneezing, runny nose, 
nasal congestion, headache), or 1 of the symptoms listed 
plus laboratory conﬁ  rmation of respiratory viral infection. 
The choice of a relatively broad clinical case deﬁ  nition was 
dictated by our interest in interrupting transmission of a 
broad range of respiratory viruses. Laboratory-conﬁ  rmed 
cases during the follow-up were deﬁ  ned by the presence of 
>1 of the symptoms listed above plus laboratory detection 
of a respiratory virus.
Study Outcomes and Analysis 
The primary study outcomes in enrolled adults were 
the presence of ILI or a laboratory diagnosis of respiratory 
virus infection within 1 week of enrollment. Given that we 
demonstrated some dual infections and that there may be a 
variable sensitivity of RT-PCR for different respiratory vi-
ruses, we included all incident infections in adults (by clini-
cal case deﬁ  nition and laboratory testing) in the analysis. 
We also measured the time from recruitment to infection. 
Causal linking of the outcomes of ILI and adherence to use 
of face masks required consideration of the timing of both.
Analysis of primary outcomes was by intention to treat. 
We performed a multivariate Cox proportional-hazards sur-
vival analysis to study secondary outcomes and determine 
how time lag from recruitment to infection of a secondary 
case-patient was affected by explanatory covariates (23). 
Gaussian random effects were incorporated in the model to 
account for the natural clustering of persons in households 
(24). The day of infection was reconstructed from the day 
of symptom onset under the assumption that the incuba-
tion period was 1–2 days. To account for exposures that oc-
curred before recruitment, the time when survival analysis 
started was deﬁ  ned as the maximum value between the day 
of recruitment minus the incubation period and the start of 
illness in the index case. (For example, assume a household 
recruited on day 0 and an incubation period of 2 days. If 
illness in the index case began on day –3, then the survival 
analysis began on day –2; if illness in the index case began 
on day –1, then the survival analysis began the same day.) 
The following variables were included in the 
models: daily adherence to use of P2 or surgical masks, 
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number of adults in the household, number of siblings 
in the household, and index case <5 years of age. This 
analysis was performed using the survival package of the 
statistical software R (www.r-project.org). Comparisons 
among groups were made with the Fisher exact test for 
categorical variables. A 2-sided p value <0.05 was con-
sidered signiﬁ  cant.
Power Analysis 
Assuming a secondary attack rate in exposed adults of 
20% and an intraclass correlation coefﬁ  cient of 30%, we 
estimated that 94 adults would be needed in each arm of 
the study to show efﬁ  cacy of >75% of P2 or surgical masks 
at 80% power and with a p value of 0.05. Our efﬁ  cacy esti-
mate was a conservative assumption based on observation-
al data for the combined effects of all mask types during the 
SARS epidemic in Hong Kong (25).
Results
Study Population 
We recruited 290 adults from 145 families; 47 house-
holds (94 enrolled adults and 180 children) were random-
ized to the surgical mask group, 46 (92 enrolled adults and 
172 children) to the P2 mask group, and 52 (104 enrolled 
adults and 192 children) to the no-mask (control) group. 
Two families in the control group were lost to follow-up 
during the study. Characteristics of the families who partic-
ipated are shown in Table 1, with no signiﬁ  cant differences 
noted among the 3 arms. 
Samples were collected from 141 children; respiratory 
viruses were detected in 90 (63.8%) children. In 79 (56.0%) 
of 141 cases, a single pathogen was detected: inﬂ  uenza A 
in 19/141 (13.5%); inﬂ  uenza B in 7/141 (4.9%); adenovi-
ruses in 7/141 (4.9%); RSV in 5/141 (3.5%); PIV in 8/141 
(5.5%) (PIV-1 in 1/141 [0.70%]; PIV-2 in 2/141 [1.4%]; 
PIV-3 in 5/141 [3.5%]); hMPV in 8/141 (5.7%); and coro-
navirus OC43 in 3/141 (2.1%). Other viruses detected in-
cluded picornaviruses in 22/141 (15.6%): rhinoviruses in 
11/22 (50.0%); enteroviruses in 5/22 (22.7%) (enterovirus 
68 in 1/5 [20.0%] and others in 4/5 [80.0%]); and uncharac-
terized nonsequenced picornaviruses in 6/22 (27.0%). An 
additional 11 children (7.8%) had dual or co-infection: 4 
(2.8%) with adenovirus and rhinovirus, 2 (1.4%) with rhi-
novirus and coronavirus; and 1 each with inﬂ  uenza A and 
enterovirus, inﬂ  uenza A and PIV-2, inﬂ  uenza A and rhino-
virus, RSV and enterovirus, and adenovirus and hMPV. 
Adherence 
Characteristics of the adherent versus nonadherent 
participants who were recruited are shown in Table 2; no 
signiﬁ  cant differences were noted between the 2 groups 
except for the presence of >3 adults in the household. On 
day 1 of mask use, 36 (38%) of the 94 surgical mask us-
ers and 42 (46%) of the 92 P2 mask users stated that they 
were wearing the mask “most or all” of the time. Other par-
ticipants were wearing face masks rarely or never. The dif-
ference between the groups was not signiﬁ  cant (p = 0.37). 
Adherence dropped to 29/94 (31%) and 23/92 (25%), re-
spectively, by day 5 of mask use (Figure 2). 
Table 3 shows reported problems with mask use. There 
were no signiﬁ  cant differences in difﬁ  culties with mask use 
between the P2 and surgical mask groups, but >50% report-
ed concerns, the main one being that wearing a face mask 
was uncomfortable. Other concerns were that the child did 
not want the parent wearing a mask and the parent forgot 
to wear the mask. Additional comments made by some in-
cluded that the mask did not ﬁ  t well and that it was not 
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Table 1. Demographic characteristics of each household by arm of randomization in the study, Sydney, New South Wales, Australia,
2006 and 2007 winter influenza seasons. 
Surgical mask group  P2 mask group 
Variable Control group, no. (%), n = 50  No. (%), n = 47  p value  No. (%), n = 46  p value 
Living arrangement 
  Reside in house  38 (76)  32 (68)  0.39 33 (72)  0.64
  >4 persons in house  13 (26)  18 (38)  0.20 19 (41)  0.11
>3 adults in house  8 (16)  11 (23)  0.36 12 (26)  0.23
Demographics 
  Caucasian race*  28 (56)  20 (43)  0.18 17 (37)  0.06
  Both adults work  28 (56)  25 (53)  0.78 27 (59)  0.79
  Smoker in house  12 (24)  12 (26)  0.86 4 (9)  0.046
Index child fully immunized  45 (90) 45 (96)  0.28 39 (85)  0.44
Index child attends childcare  37 (74) 34 (72)  0.85 27 (59)  0.11
Influenza vaccination 
  Index child  1 (2)  1 (2)  0.97 0 0.34
  1 adult vaccinated  2 (4)  2 (4)  0.95 0 0.17
Duration of child sickness†  4 5 4
Siblings reporting illness  3 (6)  1 (1)  0.34 0 0.09
*Information relates to the participating adult interviewed.  
†Median no. days. Face Masks and Respiratory Virus Transmission
practical to wear at meal time or while asleep. Some adults 
wore the mask during the day but not at night, even though 
the sick child was sleeping beside them in their bed. 
Intention-to-Treat Analysis 
ILI was reported in 21/94 (22.3%) in the surgical group, 
14/92 (15.2%) in the P2 group, and 16/100 (16.0%) in the 
control group, respectively. Samples were collected from 
43/51 (84%) sick adults, with respiratory viruses isolated 
in 17/43 (40%) sick adults. Viral pathogens were isolated 
from 6/94 (6.4%) in the surgical mask group, 8/92 (8.7%) 
in the P2 group, and 3/100 (3.0%) in the control group. In 
10/17 laboratory-positive cases, the same respiratory virus 
was isolated in the adult and the child (surgical, 3/94; P2 
group, 5/92; and control, 2/100). In 2 cases, the adult was 
the only person with a laboratory-conﬁ  rmed virus (1 each 
from the P2 and surgical groups); in the remaining 5 adults, 
the virus detected in the child differed from that in the adult 
(surgical, 2; P2 group, 2; and control group, 1). No dual 
infections were detected in the adults. Intention-to-treat 
analysis by households and by participants showed no sig-
niﬁ  cant difference between the groups (Table 4).
Risk Factors for ILI 
Under the assumption that the incubation period is 
equal to 1 day (the most probable value for the 2 most com-
mon viruses isolated, inﬂ  uenza [21] and rhinovirus [26]), 
adherent use of P2 or surgical masks signiﬁ  cantly reduces 
the risk for ILI infection, with a hazard ratio equal to 0.26 
(95% CI [conﬁ  dence interval] 0.09–0.77; p = 0.015). No 
other covariate was signiﬁ  cant. Under the less likely as-
sumption that the incubation period is equal to 2 days, the 
quantiﬁ  ed effect of complying with P2 or surgical mask 
use remains strong, although borderline signiﬁ  cant; hazard 
ratio was 0.32 (95% CI 0.11–0.98; p = 0.046). The study 
was underpowered to determine if there was a difference in 
efﬁ  cacy between P2 and surgical masks (Table 5).
Discussion
We present the results of a prospective clinical trial of 
face mask use conducted in response to an urgent need to 
clarify the clinical beneﬁ  t of using masks. The key ﬁ  nd-
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 2, February 2009  237 
Table 2. Characteristics of adherent versus nonadherent mask wearers in the study, Sydney,  New South Wales, Australia, 2006 and
2007 winter influenza seasons.* 
Variable
Fully adherent mask users, no. (%),  
n = 30 
Nonadherent mask users, no. (%),  
n = 156  p value 
Living arrangement 
  Reside in house  22  (73)  108 (69)  0.66
  >4 persons in house  11 (37)  64 (41)  0.66
>3 adults in house  3 (10)  43 (28)  0.04
Demographics 
  Caucasian race†  10 (33)  29 (19)  0.07
  Working adult  22 (73)  118 (76) 
  Smoker in house 
Daily handwashing  14 (45)  54 (34)  0.21
Use of soap when handwashing  13 (43)  65 (42)  0.87
Index child fully immunized  15 (50)  69 (44)  0.56
Index child attends childcare  6 (20)  51 (33)  0.17
Influenza vaccination 
  Index child  0 1 (0.5)  0.66
  Adult 1  0 2 (1)  0.53
  Adult 2  0 2 (1%)  0.53
Median days of child sickness  5 5
Siblings reporting illness  0 1 (0.5)  0.66
*Adherence to mask use and handwashing measured by daily self-reports and exit interviews. 
†Information relates to the participating adult interviewed. 
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Figure 2. Compliance with face mask use by day over 5 consecutive 
days during the study, Sydney,  New South Wales, Australia, 2006 
and 2007 winter inﬂ  uenza seasons.RESEARCH
ings are that <50% of participants were adherent with mask 
use and that the intention-to-treat analysis showed no dif-
ference between arms. Although our study suggests that 
community use of face masks is unlikely to be an effective 
control policy for seasonal respiratory diseases, adherent 
mask users had a signiﬁ  cant reduction in the risk for clini-
cal infection. Another recent study that examined the use 
of surgical masks and handwashing for the prevention of 
inﬂ  uenza transmission also found no signiﬁ  cant difference 
between the intervention arms (12). 
Our study found that only 21% of household contacts 
in the face mask arms reported wearing the mask often or 
always during the follow-up period. Adherence with treat-
ments and preventive measures is well known to vary de-
pending on perception of risk (27) and would be expected to 
increase during an inﬂ  uenza pandemic. During the height of 
the SARS epidemic of April and May 2003 in Hong Kong, 
adherence to infection control measures was high; 76% of 
the population wore a face mask, 65% washed their hands 
after relevant contact, and 78% covered their mouths when 
sneezing or coughing (28). In addition, adherence may vary 
depending on cultural context; Asian cultures are more ac-
cepting of mask use (29). Therefore, although we found 
that distributing masks during seasonal winter inﬂ  uenza 
outbreaks is an ineffective control measure characterized 
by low adherence, results indicate the potential efﬁ  cacy 
of masks in contexts where a larger adherence may be ex-
pected, such as during a severe inﬂ  uenza pandemic or other 
emerging infection.
We estimated that, irrespective of the assumed value 
for the incubation period (1 or 2 days), the relative reduc-
tion in the daily risk of acquiring a respiratory infection 
associated with adherent mask use (P2 or surgical) was in 
the range of 60%–80%. Those results are consistent with 
those of a simpler analysis in which persons were stratiﬁ  ed 
according to adherence (online Technical Appendix, avail-
able from www.cdc.gov/EID/content/15/2/233-Techapp.
pdf). We emphasize that this level of risk reduction is de-
pendent on the context, namely, adults in the household 
caring for a sick child after exposure to a single index case. 
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Table 3. Problems with face use reported by participants in the study, Sydney, New South Wales, Australia, 2006 and 2007 winter
influenza seasons. 
Reported problem  Surgical mask users, no. (%), n = 94  P2 mask users, no. (%), n = 92  p value 
None 46 (49)  42 (46)  0.66
Uncomfortable 16 (17)  14 (15)  0.74
Forgot to wear it  8 (9)  8 (9)  0.96
Child did not like it  6 (6)  8 (9)  0.55
Other 18 (19)  20 (22)  0.66
Table 4. Intention-to-treat analysis used in the study* 
All masks  Surgical masks  P2 masks 
Data
Control
group,
no. (%) No. (%) 
RR
(95% CI)†
p
value† No. (%) 
RR
(95% CI)†
p
value† No. (%) 
RR
(95% CI)†
p
value†
By house n = 50 n = 93 n = 47 n = 46
  ILI 12 (24) 25 (27) 1.12
(0.62–2.03)
0.84 15 (32) 1.33
(0.70–2.54)
0.50 10 (22) 0.91
(0.43–1.89)
0.81
By individual n = 100 n = 186 n = 94 n = 92
  ILI 16 (16) 33 (18) 1.11
(0.64–1.91)
0.75 19 (20) 1.29
(0.69–2.31)
0.46 14 (15) 0.95
(0.49-1.84)
1
Laboratory confirmed infections 
  Influenza A 0 3 (2) 1 (1) 2 (2)
 Influenza  B 0 1 (0.5) 0 1 (1)
 RSV 1 (1) 1 (0.5) 0 0
 hMPV 00 0 0
 Adenoviruses 0 2 (1) 0 2 (2)
 PIV‡ 1 (1) 1 (0.5) 1 (1) 0
 Coronaviruses§ 1 (1) 0 0 0
 Rhinoviruses 0 5 (3) 3 (3) 2 (2)
 Enteroviruses 00 0 0
 Picornoviruses  0 1 (0.5) 0 1 (1)
Total 3 (3) 14 (8) 2.51
(0.74–8.5)
0.19 6 (6) 2.13
(0.55–8.26)
0.32 8 (9) 2.90
(0.79–10.6)
0.12
*RR, relative risk; CI, confidence interval; ILI, influenza-like illness; RSV, respiratory syncytial virus; hMPV, human metapneumovirus; PIV, parainfluenza 
virus. 
†Reference group is the control group. 
‡Types 1–3; 229E/OC43. 
§Types 1–3. Face Masks and Respiratory Virus Transmission
We urge caution in extrapolating our results to school, 
workplace, or community contexts, or where multiple, re-
peated exposures may occur, such as in healthcare settings. 
The exact mechanism of potential clinical effectiveness of 
face mask use may be the prevention of inhalation of re-
spiratory pathogens but may also be a reduction in hand-
to-face contact. Our study could not determine the relative 
contributions of these mechanisms. 
In our study, ﬁ  t testing for P2 masks was not con-
ducted because this is unlikely to be feasible in the gen-
eral community during a pandemic. As such, we felt it was 
more appropriate to determine the efﬁ  cacy of non–ﬁ  t-test-
ed masks. We found no difference in adherence between 
P2 and surgical masks, an important ﬁ  nding, as there is a 
common belief among healthcare workers that P2 masks 
are less comfortable. The size of the study did not permit 
conclusive comparison of the relative efﬁ  cacy of P2 masks 
and surgical masks. Given the 5- to 10-fold cost difference 
between the 2 mask types, quantifying any difference in 
efﬁ  cacy between surgical masks and particulate respirators 
remains a priority that needs to be addressed by a larger 
trial. 
A possible limitation of the study is that some adults 
may have been incubating infection at the time of enroll-
ment. However, this effect would have biased the results to-
ward the null in the intention-to-treat analysis. The survival 
analysis explicitly accounted for the existence of a ﬁ  xed 
incubation period and incubating infections at the time of 
enrollment. A potential alternative study design would be 
to enroll participants from asymptomatic households, do 
follow-up for development of infection, and then immedi-
ately intervene with masks. For such a design, given that 
only 15%–20% of closely exposed adults will develop ill-
ness after exposure to an ill child, thousands of households 
(rather than hundreds) would be required to afford the same 
study power. In addition, such a design would have been 
fraught with underascertainment of incident infections and 
delayed implementation of mask intervention. We believe 
ours is a more efﬁ  cient design. A further limitation is that 
some parents may have acquired infection outside the 
home. We identiﬁ  ed 5 child–parent pairs with discordant 
viral infections. The randomization process should have 
ensured that outside exposure was equally distributed be-
tween arms, and this effect would have biased the results 
toward the null.
In retrospect, relying on laboratory-conﬁ  rmed cases as 
the primary outcome may have been unrealistic for a study 
of this size. ILI in enrolled adults was 17.1%, but laboratory 
conﬁ  rmation was modest; the virus was identiﬁ  ed in only 
34.7% of adult ILI cases (the rate of laboratory diagnosis in 
children was high at 63.8%). However, even intention-to-
treat analysis using ILI outcome shows no signiﬁ  cant dif-
ference between the groups. We used self-reporting to de-
termine adherence; previous research indicates that patient 
self-reporting is more reliable than judgments by doctors 
or nurses when compared against urine drug levels (30). 
In addition, the signiﬁ  cant association between adherence 
and clinical protection provides internal validation of self-
reporting as a measure.
An important aspect of this study is that we included 
respiratory viruses other than inﬂ  uenza. Although these 
viruses may differ in their relative dependence (accurate 
quantitation of this relativity is uncertain for the various 
viruses) on different transmission mechanisms (i.e., large 
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Table 5. Estimates of hazard ratios for ILI in the study* 
Global effect of mask use  Effect per mask type 
Variable Hazard ratio (95% CI)  p value  Hazard ratio (95% CI)  p value 
1-d incubation period 
  Adherence to use of surgical or P2 mask†  0.26 (0.09–0.77)  0.015‡
  Adherence to use of surgical mask†  0.27 (0.06–1.24)  0.09
  Adherence to use of P2 mask†  0.24 (0.05–1.08)  0.06
  No. adults  1.07 (0.66–1.71)  0.80 1.06 (0.66–1.71)  0.80
  No. siblings  0.86 (0.55–1.35)  0.52 0.86 (0.55–1.35)  0.52
  Index patient <5 y of age  0.88 (0.41–1.89)  0.75 0.88 (0.41–1.89)  0.74
 Frailty§  0.005‡ 0.004‡
2- d  incubation period 
  Adherence to use of surgical or P2 mask†  0.32 (0.11–0.98)  0.046‡
  Adherence to use of surgical mask†  0.18 (0.02–1.38)  0.099
  Adherence to use of P2 mask†  0.45 (0.12–1.62)  0.22
  No. adults  1.13 (0.71–1.81)  0.60 1.14 (0.71–1.82)  0.59
  No. siblings  0.80 (0.51–1.27)  0.34 0.80 (0.50–1.27)  0.34
  Index patient <5 y of age  1.02 (0.46–2.24)  0.96 1.02 (0.47–2.25)  0.95
 Frailty§  0.004‡ 0.004‡
*ILI, influenza-like illness; CI, confidence interval.  
†Time-dependent variable. 
‡p<0.05 significant (indicates that the outcome for 1 person is correlated with the outcome of other persons in the household).
§This term measures if the clustering of subjects in households is relevant to quantify the risk of ILI infection.  RESEARCH
droplet, aerosol, or fomite), all are transmitted by the respi-
ratory route. Therefore, face mask use should have some 
effect on virus transmission (e.g., interference with hand-
nose contact), given that participants in all arms of the study 
received the same infection control advice. In addition, we 
argue that assessing multiple respiratory viruses allows our 
results to be generalized more broadly to other infections, 
including new respiratory viruses that may emerge in the 
future. Conversely, the low rate of conﬁ  rmed inﬂ  uenza A 
or B infection (18.4%) in the study could mean that our 
ﬁ  ndings are not directly applicable to a scenario in which 
inﬂ  uenza predominates. If inﬂ  uenza is more likely than the 
other viruses in our study to be transmitted by the respira-
tory route, the prevalence of mixed infections would tend 
to bias our results toward the null. However, it is possible 
that a pandemic strain may have different transmission 
characteristics than seasonal strains as demonstrated by at-
tack rates in different age groups in pandemics compared 
with seasonal outbreaks and by the detection of inﬂ  uenza 
virus in different clinical samples in human inﬂ  uenza virus 
A (H5N1) cases. 
Results of our study have global relevance to respi-
ratory disease control planning, especially with regard to 
home care. During an inﬂ  uenza pandemic, supplies of an-
tiviral drugs may be limited, and there will be unavoidable 
delays in the production of a matched pandemic vaccine 
(31). For new or emerging respiratory virus infections, no 
pharmaceutical interventions may be available. Even with 
seasonal inﬂ  uenza, widespread oseltamivir resistance in in-
ﬂ  uenza virus A (H1N1) strains have recently been reported 
(32). Masks may therefore play an important role in reduc-
ing transmission. 
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